B of A Securities raises Taysha price target to $10

0 min read     Updated on 23 Jun 2026, 08:16 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

B of A Securities analyst Tazeen Ahmad maintained a Buy rating on Taysha Gene Therapies and raised the price target to $10 from $9.

powered bylight_fuzz_icon
43771550

*this image is generated using AI for illustrative purposes only.

B of A Securities analyst Tazeen Ahmad has maintained a Buy rating on Taysha Gene Therapies. The firm raised the price target to $10 from $9.

Rating and Target Details

The revised price target reflects an increased valuation outlook for the company. The previous target was $9.

Metric Value
Rating Buy
New Price Target $10
Previous Price Target $9

What specific factors drove the increased valuation outlook for Taysha Gene Therapies?

How might this rating change influence investor sentiment in the biotech sector?

What upcoming clinical milestones could further impact the stock's performance?

like20
dislike

Citizens raises Taysha price target to $11, maintains outperform

0 min read     Updated on 23 Jun 2026, 07:31 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Citizens analyst Silvan Tuerkcan maintained a Market Outperform rating on Taysha Gene Therapies and increased the price target from $8 to $11.

powered bylight_fuzz_icon
43768904

*this image is generated using AI for illustrative purposes only.

Citizens analyst Silvan Tuerkcan has maintained a Market Outperform rating on Taysha Gene Therapies and raised the price target to $11. The previous target was $8. The company trades on the NASDAQ under the ticker symbol TSHA.

Rating and Target Details

The revised price target reflects an increased valuation outlook for the biotechnology firm. The Market Outperform rating indicates expectations for the stock to perform better than the broader market average.

Metric Value
Rating Market Outperform
New Price Target $11
Previous Price Target $8

What specific factors drove the 37.5% increase in Taysha's price target?

How might this rating upgrade influence investor sentiment towards Taysha in the short term?

What upcoming clinical milestones could further impact Taysha's stock performance?

like16
dislike

More News on Taysha Gene Therapies Inc